KRAS and non-small cell lung carcinoma: Similarly, in the KEYNOTE-189 trial, a post-hoc analysis revealed that patients with NSCLC who presented with any KRAS mutations and those with the KRAS-G12C mutation who received pembrolizumab plus chemotherapy achieved better outcomes than those who received chemotherapy alone [20].